Medicare's GLOBE drug-price rule now hits four drugmakers; projected savings fall 96% to $440 million
The final rule exempts companies that signed pricing deals with the White House. What is left saves about $80 million a year, and the part that touches doctors' offices is a coinsurance cut in a quarter of the country.
The Trump administration's mandatory Medicare drug-pricing experiment for physician-administered drugs will apply to just four manufacturers, according to the final rule published on Wednesday evening. Medicare's regulator plans to waive participation for drugmakers that have signed separate "most favored nation" deals with the White House, Reuters reported. More than two dozen companies have signed such deals, including Pfizer, Eli Lilly and Novo Nordisk. The rule does not name the four that remain.
The change shows up in the government's own math. The final rule estimates the model, called GLOBE, will cut Medicare Part B net spending by $440 million over its seven-year payment period. When the model was proposed, the projection was about $11.9 billion, Reuters reported. STAT first reported the reduction.
The number behind the number
$440 million against $11.9 billion is a 96% cut. The rule itself says that annualized, the savings come to about $80 million a year. The $440 million is a net figure: $298 million in traditional Medicare benefit savings plus $288 million in Medicare Advantage payment savings, minus a $147 million premium offset. Medicaid gets another $39 million.
The model works by charging manufacturers a rebate when US prices for certain Part B drugs run above an international benchmark. With most of the large drugmakers exempted through their own deals, the rebate base shrank, and so did the savings. For drug stocks, that makes GLOBE a much smaller event than it looked when proposed: most of the largest drugmakers, Reuters reported, are among those with deals.
The timeline
- Jan. 1, 2027: voluntary collection of international pricing data from manufacturers begins.
- April 1, 2027 to March 31, 2032: five performance years, when reduced patient coinsurance applies.
- Through March 31, 2034: payment period, when CMS invoices and collects the rebates.
The model covers only a random selection of ZIP code areas holding about 25% of traditional Medicare Part B enrollees, according to the rule.
Who it actually hits: the practices that bill these drugs
Doctors are not participants, but they handle the money. Physician practices, hospital outpatient departments and ambulatory surgery centers that give GLOBE drugs to patients in the selected areas will keep buying and billing as usual, the rule says. What changes is the split of each payment. In the rule's own example, on a drug with a $100 Medicare allowed amount where coinsurance drops to 10%, Medicare pays the practice $90 instead of $80 and the patient owes $10 instead of $20.
For an oncology or infusion practice, that is a cash-flow improvement: more of each claim is paid by Medicare directly and less has to be collected from the patient afterwards. The rule says that using 2024 data, 94% of illustrative GLOBE drugs would carry patient coinsurance of 2% to 12%, against the standard 20%. The catch is administrative. Billing staff will need to know which patients live in a GLOBE area and which drugs qualify, from April 2027.
The rule notes that patients with supplemental coverage may not see the coinsurance cut directly, though all Part B enrollees may see slightly lower premiums.
There are 27,996 independent medical practices listed on CheckThisBiz, with the most in Texas (2,926), California (2,515) and Florida (2,103). Most will see little change. The ones that do are specialty practices administering expensive biologics in one of the selected ZIP areas.
The Department of Health and Human Services did not respond to Reuters' questions about the reduced savings. A second mandatory pilot, GUARD, remains at the proposal stage, STAT reported.
Sources: CMS GLOBE Model final rule (Federal Register public inspection); Reuters via Investing.com; STAT; business counts from CheckThisBiz. This is market information, not investment advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

